Jackson Creek Investment Advisors LLC Purchases New Stake in Blueprint Medicines Co. (NASDAQ:BPMC)

Jackson Creek Investment Advisors LLC purchased a new stake in Blueprint Medicines Co. (NASDAQ:BPMC) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,498 shares of the biotechnology company’s stock, valued at approximately $1,430,000. Blueprint Medicines makes up approximately 0.5% of Jackson Creek Investment Advisors LLC’s portfolio, making the stock its 17th largest position.

Several other institutional investors have also recently added to or reduced their stakes in BPMC. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Blueprint Medicines by 0.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,414 shares of the biotechnology company’s stock worth $3,451,000 after acquiring an additional 145 shares during the last quarter. Van ECK Associates Corp grew its position in shares of Blueprint Medicines by 28.4% during the fourth quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 193 shares during the last quarter. Diversified Trust Co grew its position in shares of Blueprint Medicines by 2.9% during the third quarter. Diversified Trust Co now owns 11,219 shares of the biotechnology company’s stock worth $563,000 after acquiring an additional 318 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of Blueprint Medicines by 63.4% during the third quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 329 shares during the last quarter. Finally, Los Angeles Capital Management LLC grew its position in shares of Blueprint Medicines by 2.5% during the third quarter. Los Angeles Capital Management LLC now owns 14,493 shares of the biotechnology company’s stock worth $728,000 after acquiring an additional 355 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts recently weighed in on BPMC shares. JMP Securities reaffirmed a “market outperform” rating and issued a $114.00 price objective on shares of Blueprint Medicines in a report on Wednesday, April 10th. Barclays upped their price objective on shares of Blueprint Medicines from $58.00 to $70.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $97.00 price objective on shares of Blueprint Medicines in a report on Friday. Citigroup upped their price objective on shares of Blueprint Medicines from $54.00 to $65.00 and gave the stock a “sell” rating in a report on Friday, February 16th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $110.00 price objective on shares of Blueprint Medicines in a report on Friday. Four analysts have rated the stock with a sell rating, two have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $91.57.

Blueprint Medicines Trading Down 1.9 %

Shares of BPMC traded down $1.76 during midday trading on Tuesday, hitting $91.34. The stock had a trading volume of 517,046 shares, compared to its average volume of 759,258. Blueprint Medicines Co. has a fifty-two week low of $43.89 and a fifty-two week high of $101.00. The business has a 50-day simple moving average of $90.85 and a two-hundred day simple moving average of $79.52. The firm has a market cap of $5.59 billion, a P/E ratio of -10.93 and a beta of 0.63. The company has a current ratio of 3.76, a quick ratio of 3.66 and a debt-to-equity ratio of 1.60.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.04) by $0.22. The business had revenue of $71.96 million during the quarter, compared to analyst estimates of $67.34 million. Blueprint Medicines had a negative net margin of 203.30% and a negative return on equity of 191.56%. The firm’s revenue was up 85.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.65) earnings per share. As a group, equities analysts forecast that Blueprint Medicines Co. will post -5.41 EPS for the current year.

Insider Transactions at Blueprint Medicines

In other news, EVP Tracey L. Mccain sold 5,194 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $90.69, for a total value of $471,043.86. Following the completion of the sale, the executive vice president now directly owns 60,498 shares of the company’s stock, valued at $5,486,563.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Tracey L. Mccain sold 5,194 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $90.69, for a total transaction of $471,043.86. Following the transaction, the executive vice president now owns 60,498 shares of the company’s stock, valued at $5,486,563.62. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Michael Landsittel sold 5,003 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $90.69, for a total transaction of $453,722.07. Following the transaction, the chief financial officer now directly owns 56,020 shares in the company, valued at approximately $5,080,453.80. The disclosure for this sale can be found here. Insiders sold 92,289 shares of company stock valued at $8,314,163 over the last three months. 3.88% of the stock is owned by corporate insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.